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Tumour-derived extracellular vesicles in blood of metastatic
cancer patients associate with overall survival
Afroditi Nanou1, M. Craig Miller2, Leonie L. Zeune1, Sanne de Wit1, Cornelis J. A. Punt3, Harry J. M. Groen4, Daniel F. Hayes5,
Johann S. de Bono6,7 and Leon W. M. M. Terstappen1
BACKGROUND: Circulating tumour cells (CTCs) in blood associate with overall survival (OS) of cancer patients, but they are
detected in extremely low numbers. Large tumour-derived extracellular vesicles (tdEVs) in castration-resistant prostate cancer
(CRPC) patients are present at around 20 times higher frequencies than CTCs and have equivalent prognostic power. In this study,
we explored the presence of tdEVs in other cancers and their association with OS.
METHODS: The open-source ACCEPT software was used to automatically enumerate tdEVs in digitally stored CellSearch® images
obtained from previously reported CTC studies evaluating OS in 190 CRPC, 450 metastatic colorectal cancer (mCRC), 179 metastatic
breast cancer (MBC) and 137 non-small cell lung cancer (NSCLC) patients before the initiation of a new treatment.
RESULTS: Presence of unfavourable CTCs and tdEVs is predictive of OS, with respective hazard ratios (HRs) of 2.4 and 2.2 in CRPC,
2.7 and 2.2 in MBC, 2.3 and 1.9 in mCRC and 2.0 and 2.4 in NSCLC, respectively.
CONCLUSIONS: tdEVs have equivalent prognostic value as CTCs in the investigated metastatic cancers. CRPC, mCRC, and MBC (but
not NSCLC) patients with favourable CTC counts can be further prognostically stratified using tdEVs. Our data suggest that tdEVs
could be used in clinical decision-making.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0726-9
BACKGROUND
Characterisation of a patient’s tumour is frequently assessed on
the primary tumour. However, it is well recognised that the
phenotype of a tumour is highly heterogeneous; hence, a biopsy
in a selective area is very restrictive in representing the whole
tumour.1,2 Moreover, the lesions in metastatic sites further
complicate the tumour pattern as they can have substantially
different features than the primary tumour.3–5 In addition,
tumours evolve over time and treatments while developing
drug-resistance mechanisms.6 From these observations emerge
the importance of a biopsy that could provide clinicians with real-
time data to facilitate treatment decision-making. In theory,
subsequent collections of solid biopsies from multiple sites could
be a solution; however, in practice, not all sites are accessible by
surgery and such a procedure is highly invasive leading to patient
discomfort and health complications. On the other hand, liquid
biopsies require a minimally invasive biofluid sampling; conse-
quently, they can be performed in short time intervals providing
clinicians with a real-time snapshot of the disease.7 Importantly,
the detected tumour material in biofluids, namely circulating
tumour cells (CTCs), tumour-derived extracellular vesicles (tdEVs)
and circulating tumour DNA (ctDNA), is clinically relevant and can
better reflect the characteristics of the metastatic sites.8
Specifically, the field of tdEVs has gained a lot of attention
during the past few years, mainly because of their increased
prevalence and promise as potential biomarkers to aid in the
disease management of cancer patients.9–15 The reported size
range of tdEVs varies between 30 and 10,000 nm, with the
diameter of exosomes being 30–300 nm, of microvesicles <1000
nm and of large oncosomes between 1000 and 10,000 nm.16–18
All different tdEV subclasses have been reported to play various
roles directly related to the disease progression and metastatic
processes.19–25 However, the isolation, enumeration, differentia-
tion and molecular profiling of pure tdEVs from the blood
of cancer patients is challenging because of all the contaminants
present, including proteins, protein aggregates, free nucleic
acids (RNA and DNA), platelets and EVs of different cell
origins.26,27 Hence, enrichment and/or depletion techniques
are necessary for the specific isolation of tdEVs and their
downstream characterisation.
Previously, our group reported the presence of EpCAM+, CK+,
DNA−, CD45− “tumour microparticles” and “CTC fragments” that
were considered by-products of cancer apoptosis.28,29 These
particles have relatively large sizes (>1 μm) and can be isolated
together with CTCs from 7.5mL of peripheral blood after
immunomagnetic selection targeting the epithelial cell adhesion
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molecule (EpCAM) expressed on their surface membrane. We used
the term tumour-derived EVs (tdEVs) to describe these objects. The
isolation and labelling of the EpCAM enriched sample is performed
using the Food and Drug Administration (FDA)-cleared CellSearch®
system. For the automated enumeration of tdEVs, the open-source
ACCEPT software (http://github.com/LeonieZ/ACCEPT) was used.
ACCEPT segments all detected objects in the fluorescence images
and measures 10 parameters in each fluorescence channel
regarding their morphology and fluorescence intensity. By defining
and applying linear gates, different classes of objects (leukocytes,
CTCs, tdEVs) found in the fluorescence CellSearch images can be
enumerated in an automated manner. Following that approach,
we previously reported that these large tdEVs are present in the
blood of castration-resistant prostate cancer (CRPC) patients in
approximately 20 times higher frequencies compared to CTCs and
have a significant association with poor prognosis.14 Here we
explore whether the presence of EpCAM+, CK+, DNA−, CD45−
tdEVs in metastatic breast cancer (MBC), metastatic colorectal
cancer (mCRC), and non-small cell lung cancer (NSCLC) patients is
associated with overall survival (OS) and we determine whether or
not tdEVs can further improve prognostication of cancer patients.
METHODS
Patient samples
One hundred and ninety CRPC (IMMC38 clinical trial, NCT00133900),30
450 mCRC (CAIRO II clinical trial, NCT00208546),31,32 179 MBC
(IMMC01 clinical trial),33 and 137 NSCLC patient samples,34–36 along
with 93 healthy control samples (IMMC06 clinical trial,
NCT00133913),37 were included. The included samples corresponded
to patients before the initiation of a new treatment. Patient
characteristics are provided in Table 1. All individuals provided
written informed consent prior to participation in the trial protocols
approved by institutional review boards at the participating centres of
the studies.31–38
Isolation and identification of CTCs and tdEVs
Digitally stored CellSearch® (Menarini Silicon Biosystems, Hun-
tingdon Valley, PA, USA) image files from the abovementioned
CTC studies were re-analysed. Briefly, CTCs and tdEVs were
immunomagnetically isolated from 7.5 mL of peripheral blood
collected in Cell Save tubes using the CellSearch system.
The EpCAM-enriched cells were stained with the nucleic acid
dye 4,6-diamidino-2-phenylindole (DAPI) and the staining reagent
of the CTC kit including mouse monoclonal antibodies against
CD45 (clone HI30) conjugated to allophycocyanin (APC) and
mouse monoclonal antibodies against cytokeratins (CKs) 8, 18 and
19 (clones C11 and A53-B/A2) conjugated to phycoerythrin (PE). In
case of CRPC, MBC and mCRC, no extra markers were used in the
fluorescein isothiocyanate (FITC) and peridinin chlorophyll protein
(PerCP) channels. In case of NSCLC, the EpCAM-enriched cells had
been additionally labelled with mouse monoclonal antibodies
against CD16 (clone 3G8) conjugated to PerCP (Marker 2) and in
some of the cases with the wheat germ agglutinin conjugated to
Alexa 488 (Marker 1) or with mouse monoclonal antibodies
against CKs 1–8, 10, 14, 15, 16, 19, 20 (clones LP5K, Ks20.10 and
AE1/AE4) conjugated to FITC (Marker 1) to address research points
of previously reported studies. The subsets of patient samples
with additional Marker 1 or/and 2 labelling can be found in
Supplementary Table S1. The immunofluorescently stained
suspension was placed in a cartridge contained within a Magnest®
as previously described.37 The image acquisition was performed
on the CellSpotterTM Analyzer for the older IMMC01 study (MBC)
and the healthy donors included in the IMMC06 study. The image
acquisition of the IMMC38 (CRPC), CAIRO II (mCRC) and NSCLC
studies was performed on the CellTracks® Analyzer IITM. Both
systems are semi-automated fluorescence microscopes equipped
with computer-controlled X, Y, Z stages, a NA 0.45 ×10 objective,
a Mercury Arc lamp, a 12-bit CCD camera and filter cubes for DAPI,
PE, APC and FITC. Typically, 175 images per channel are taken to
cover the entire surface of the cartridge.39
CTC counts and automated enumeration of tdEVs with ACCEPT
To obtain accurate counts of CTCs and tdEVs, the manual CTC
counts were extracted from the CellTracks Analyzer II. For tdEV
enumeration, the digitally stored fluorescence image files were re-
analysed with the open-source ACCEPT software v1.1 (http://
github.com/LeonieZ/ACCEPT) using the “Full Detection” function.
After that analysis, 10 morphological and fluorescence signal
intensity measurements, for each object found in the images, are
extracted per channel. These measurements can be used to
design linear gates to identify different classes of objects in
the images.14,34 The definition of tdEVs in case of CRPC, MBC,
mCRC was EpCAM+, CK+, DAPI−, CD45− particles of a diameter
<14 μm. The background PE fluorescence in the images acquired
on the CellSpotter Analyzer was higher compared to the
CellTracks Analyzer II, resulting in the use of a different tdEV gate
for each platform. The applied tdEV gate for images acquired on
CellTracks Analyzer II was: Mean Intensity CD45 ≤5, Mean Intensity
DNA ≤5, Mean Intensity CK >60, Mean Intensity Marker 1 ≤5, Mean
Intensity Marker 2 ≤5, Max Intensity CK >90, Size CK ≤150 μm2,
Perimeter CK >5 pixels, Eccentricity CK ≤0.8, and Perimeter to Area
CK ≤1.14 For the images acquired on the CellSpotter, the setting of
Standard Deviation for CK >40 was implemented in the tdEV gate
instead of the CK Max Intensity. In case of NSCLC, tdEVs should be
additionally CD16− (an already included criterion in the afore-
mentioned tdEV gate as Mean Intensity Marker 2 ≤5). However,
tdEVs could be either positive or negative for Marker 1 (wheat
germ agglutinin or CKs 1–8, 10, 14, 15, 16, 19, 20). In order to be
able to compare among different NSCLC patient samples, we did
not include any requirements for the Mean Intensity Marker 1.
Statistical analysis
Statistical analysis was performed using SPSS 23.0 (SPSS Inc.,
Chicago, IL, USA). For each cancer type, a two-tailed Spearman’s
Rho test was performed to evaluate the relation between the CTC
and tdEV counts. The non-parametric Wilcoxon Signed Ranks test
was used to test the equality of the distributions for the matched
CTC and tdEV counts within each cancer type. The non-parametric
Mann–Whitney U test was used to test the equality of the
distributions for the CTC and tdEV counts in the healthy donors
compared to each patient cohort as well as all patients together.
OS for each patient was defined as the elapsed time in months
between the baseline blood draw date and the date of death or
the date of last follow-up. Patients alive at the end of the study or
lost during the follow-up period were censored. Median OS was
estimated by Kaplan–Meier (KM) survival curves and survival
curves for favourable and unfavourable groups based on CTC and/
or tdEV counts were compared using the non-parametric log-rank
test. Cox proportional hazards regression analysis was used to
determine the univariable hazard ratios (HRs) for OS with 95%
confidence intervals (CIs). A final multivariable Cox model for each
cancer type was fit including the significant variables from the
univariable Cox proportional hazards regression analysis. Owing to
correlation between some of the included variables, the final
model was selected using forward stepwise elimination (pin= 0.05
and pout= 0.10). The open-source web application Cutoff Finder
(http://molpath.charite.de/cutoff) was used to calculate the HRs
for OS with 95% CIs over a wide range of cut-off values for the CTC
and tdEV counts for the full data sets as well as for tdEV counts in
the subset of patients with favourable CTC counts. The optimal
cut-off values of tdEVs for patients with favourable CTCs were
defined as the points with the most significant split (log-rank test).
Cutoff Finder uses the R code to provide optimisation and
visualisation tools for cut-off determination.40 Receiver operating
characteristic (ROC) curves were used for each cancer type to
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assess the performance of CTCs and tdEVs in classifying patients
based on shorter than median OS or death.
RESULTS
ACCEPT display of CTCs and tdEVs
All objects found in the fluorescence images are visualised using
the quantitative display of the ACCEPT toolbox. Figure 1 shows
examples of manually scored CTCs and automatically scored tdEVs
found in the CellSearch images.
CTC and tdEV frequencies in CRPC, MBC, mCRC and NSCLC
The frequencies of EpCAM+ CTCs and tdEVs identified in blood
samples obtained from CRPC, MBC, mCRC and NSCLC patients are
provided in Fig. 2. Samples from 93 healthy donors were included
as a reference. The CTC distribution of healthy donors was highly
significantly different compared to the respective distribution of
CRPC, MBC and NSCLC (p < 0.001, Mann–Whitney U test) but not
mCRC (p > 0.05, Mann–Whitney U test). In case of tdEVs, the
distribution of healthy donors was highly significantly different
compared to the respective distribution of CRPC, MBC and mCRC,
but not NSCLC. Comparison of the pooled patient CTC and tdEV
data set to the reference data set of healthy donors resulted in a
highly significantly different distribution of only tdEVs. Notably,
the median and average tdEV counts are an order of magnitude
higher compared to the respective CTC counts (p < 0.01, Wilcoxon
Signed Ranks test), with 96.4% of all patients (186/190 CRPC,
169/179 MBC, 448/450 mCRC and 119/137 NSCLC patients) having
higher tdEV counts. CRPC patients had the highest median CTC
and tdEV counts, followed by MBC, mCRC and NSCLC patients.
Table 1. Patient characteristics.
Metastatic cancer patients CRPCa MBC mCRC NSCLC
Number of patients 190 179 450 137
Age (years)
Median (range) 70 (49–92) 59 (27–86) 63 (27–83) 65 (29–83)
Gender
Male 190 (100%) 0 (0%) 271 (60%) 74 (54%)
Female 0 (0%) 179 (100%) 179 (40%) 63 (46%)
Unknown 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ECOG performance status
0 87 (46%) 83 (46%) 286 (64%) 78 (57%)
1 80 (42%) 73 (41%) 153 (34%) 49 (36%)
2 17 (9%) 17 (10%) 2 (0%) 5 (4%)
3 0 (0%) 1 (1%)
4 0 (0%) 0 (0%)
Unknown 6 (3%) 5 (3%) 9 (2%) 5 (4%)
Line of therapy
1 132 (70%) 75 (42%) 450 (100%) 36 (26%)
2 29 (15%) 27 (15%) 21 (15%)
3+ 29 (15%) 75 (42%) 80 (59%)
Unknown 2 (1%)
Therapy type started after blood draw
Chemotherapy 11 (6%) 75 (42%) 32 (23%)
Hormone 45 (25%)
Molecular 8 (4%) 20 (15%)
Immunotherapy 80 (58%)
Other 1 (1%)
Chemotherapy/hormone 126 (66%) 11 (6%)
Chemotherapy/molecular 23 (13%) 450 (100%)




Unknown 1 (1%) 5 (3%) 5 (4%)
Follow-up time (in months), median (min–max)
Alive 30.4 (1.9–39.0) 20.6 (1.3–48.8) 20.2 (0.0–34.0) 8.8 (0.7–30.1)
Dead 11.6 (0.7–39.3) 9.9 (0.4–31.7) 12.2 (0.4–32.3) 4.6 (0.7–25.3)
Status at last follow-up
Alive 53 (28%) 77 (43%) 194 (43%) 68 (50%)
Dead 137 (72%) 102 (57%) 256 (57%) 69 (50%)
aIn case of CRPC, the line of therapy refers to the line of cytotoxic therapy
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CTC and tdEV counts were significantly correlated in all cancer
types, as illustrated in Supplementary Fig. S1. The correlation
coefficient between CTC and tdEV counts in these cancer types
were tested using Spearman’s Rho test and was found to be 0.87
for CRPC (p < 0.001), 0.70 for MBC and mCRC (p < 0.001) and 0.44
for NSCLC cancer (p < 0.001).
Owing to skewed distribution, we chose to use the median
value plus 2 standard deviations (SD) of tdEV counts detected in
the 93 healthy donors as a normal reference range. This resulted in
a normal range of 0–20 tdEVs per 7.5 mL of blood.
Association of CTCs and tdEVs with OS in cancer patients
The association of CTCs and tdEVs in CRPC, MBC, mCRC and NSCLC
with OS was evaluated using KM plots (Fig. 3). For CTCs, the same
cut-offs established in the original studies (5 for CRPC and MBC
and 3 for mCRC) were used to dichotomise patients into
favourable and unfavourable CTC groups. For NSCLC patients, 1
CTC was used as a cut-off. For tdEVs, the cut-off value used to
dichotomise patients into groups with favourable and unfavour-
able tdEVs was defined as the upper bound of the normal
reference range (≥20 tdEVs). Univariable Cox proportional hazards
regression analysis was used to estimate the HR for OS between
the favourable and unfavourable CTC and tdEV groups. As shown
in Fig. 3, cancer patients with ≥20 tdEVs/7.5 mL have an
approximately twofold higher risk of death compared to patients
with <20 tdEVs (p < 0.05, log-rank test). The stratification of the
same patients based on their CTC counts resulted in slightly
higher HRs for OS in all cancer types, except for NSCLC, where the
HR was slightly higher for tdEVs (p < 0.05, log-rank test, Fig. 3).
To demonstrate the association between increasing CTC and
tdEV load and OS, KM plots were generated. For this analysis, CTCs
and tdEVs for each cancer type were binned into four groups,
except for the CTC analysis of mCRC and NSCLC, where the CTC
counts were binned into only three groups because the majority
of patients did not have CTCs. As shown in Fig. 4, increasing tdEV
load in the blood of cancer patients (Fig. 4b) is significantly
associated with worsening OS. The same pattern can be seen for
CTCs (Fig. 4a), although the narrower range of CTC values leads to
more unequal numbers of patients in each risk group compared to
their stratification based on tdEV values.
To investigate the dependence of HR for all four different cancer
types on different cut-off values for both CTCs and tdEVs,
overview plots of HR (including 95% CIs) for OS were generated
by the open-source Cutoff Finder web application (Supplementary
Fig. S2). For CRPC, MBC and mCRC cancer, >94% of all possible cut-
off values for both CTCs and tdEVs lead to a significant
dichotomisation of patients for OS. For NSCLC, all of the possible
CTC cut-off values and 67% of possible tdEV thresholds resulted in
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Fig. 1 Examples of objects manually classified as CTCs by individual
users (a) or automatically classified as tdEVs using the open-source
ACCEPT software (b) on images obtained from CRPC, MBC, mCRC
and NSCLC cancer patients. The red contours around the objects
indicate the contours as detected by the ACCEPT image analysis
algorithm. All objects were isolated from 7.5 mL of blood using the


































Fig. 2 Dot plots of manual CTC counts (in black) and automated tdEV counts (in grey) in the blood of individuals with different cancer
types. Horizontal black lines indicate median values. tdEV counts are significantly higher compared to the respective CTC counts in CRPC,
MBC, mCRC and NSCLC cancer patients (p < 0.05 for all 4 comparisons, Wilcoxon Signed Ranks test). CTC and tdEV counts of 93 healthy donors
were used as a reference.
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Fig. 3 Kaplan–Meier plots for overall survival in CRPC, MBC, mCRC and NSCLC patients with favourable and unfavourable CTC (a) and tdEV
(b) counts using different cut-off values for CTCs (5 for CRPC and MBC, 3 for mCRC and 1 for NSCLC) and the same cut-off value of
20 for tdEVs.
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Fig. 4 Kaplan–Meier plots for overall survival in CRPC, MBC, mCRC and NSCLC patients with increasing levels of CTCs (a) and tdEVs (b).
Increasing tdEV counts are associated with worse OS in all cancer types, similarly to CTCs.
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overview plots, it is clear that HRs for both CTCs and tdEVs in all
different cancer types are similar.
The overlap of ROC curves that were generated to evaluate the
performance of CTCs and tdEVs in classifying patients based on
their OS and experiencing death (Supplementary Fig. S3) further
supports the finding that CTCs and tdEVs are equivalent
prognostic biomarkers of OS.
Stratification of patients with favourable CTC counts based on
tdEVs
To evaluate whether patients with favourable CTC counts could be
further stratified using tdEVs, the Cutoff Finder web application
was used to plot the resulting HRs (with 95% CI) against the
different cut-off values of tdEVs for each cancer type (Fig. 5a–c).
For CRPC, the optimal tdEV cut-off (i.e. the cut-off leading to the
highest HR with a p value <0.001, log-rank test) was ≥89, with 13%
of the patients with favourable CTC counts having elevated
(unfavourable) tdEV counts. For MBC, the optimal tdEV cut-off was
≥80, with 11% of the patients with favourable CTC counts having
elevated tdEVs. For mCRC, the optimal tdEV cut-off was ≥40, with
24% of the patients with favourable CTC counts having unfavour-
able tdEV counts. For NSCLC, no cut-off value for tdEVs was found
that led to a significant dichotomisation of patients with
favourable CTC counts. KM plots were generated for patients
with favourable CTC counts based on the aforementioned optimal
tdEV cut-off values for each cancer (Fig. 5d–f). Patients with
unfavourable tdEV counts had significantly worse OS in compar-
ison to patients with favourable tdEV counts, with a 4.7-fold higher
risk of death (95% CI: 2.2–10.3) in CRPC, a 4.9-fold higher risk (95%
CI: 2.2–11.2) in MBC and a 2-fold higher risk (95% CI: 1.5–2.9) in
mCRC.
Univariable and multivariable associations between potential risk
factors and OS of CRPC, MBC, mCRC and NSCLC patients
Different variables for each cancer type were evaluated as
potential risk factors of OS using univariable Cox proportional
hazards regression analysis (Supplementary Table S2). For the
multivariable analysis, the significant predictors of the univariable
analysis were included (Supplementary Table S3).
In case of CRPC, the tested variables were age, Eastern
Cooperative Oncology Group (ECOG) status, haemoglobin and
the log-transformed CTCs, tdEVs, prostate-specific antigen, lactate
dehydrogenase (LDH), alkaline phosphatase, albumin and testos-
terone. All variables, except for testosterone, were significant and
used as input variables in the multivariable regression analysis.
The final multivariable model included ECOG status, age,
haemoglobin, tdEVs and LDH.
In case of MBC, ECOG status, age, oestrogen receptor, HER2 and
progesterone receptor (PR) status of the tumour, time to
metastasis, number of metastatic sites, line of therapy, type of
therapy and log-transformed CTCs and tdEVs were evaluated as
potential risk factors. ECOG status, PR status, number of metastatic
sites, type of therapy, CTCs and tdEVs were significant and used as
input variables in the multivariable regression analysis. The final
multivariable model included the number of metastatic sites,
ECOG status and CTCs.
In case of mCRC, the tested variables were the treatment arm,
ECOG status, age, LDH (normal versus abnormal), gender, prior
adjuvant therapy, >1 affected organs and the log-transformed
CTCs and tdEVs. All variables apart from the treatment arm, the
prior adjuvant therapy and the gender were significant predictors
of OS and were used as input variables in the multivariable
regression analysis. The final multivariable model included the
ECOG status, age and both CTCs and tdEVs.
In case of NSCLC, the tested variables were the ECOG status,
type of treatment, age, gender and the log-transformed CTCs and
tdEVs. Except for the type of treatment, all variables were
significant predictors of OS and used as input variables in the
multivariable regression analysis. The final multivariable model
included the ECOG status, age and CTCs.
DISCUSSION
The FDA-cleared CellSearch® system presents thumbnail images
containing CK-PE and DAPI signals to the operator for manual
classification of CTCs.39 The operator bias in CTC classification can
be improved by providing quantitative information of the objects
in the thumbnails and can be eliminated by the use of gates with
the open-source ACCEPT software (http://github.com/LeonieZ/
ACCEPT).14,41–43 Further improvements in the classification of CTCs
can be obtained through the use of deep learning;44 however, for
its implementation on larger data sets, significant improvements
in the software are still needed. Therefore, in this study, we elected
to use the original CTC scores of the studies. The introduced
operator bias together with the assay variations and the low cut-
off values of 1, 3 and 5 CTCs per 7.5 mL of blood make an accurate
assessment impossible. As an example, two separate tubes of
blood drawn from the same patient at the same time could very
likely show that one tube had four CTCs, while the other tube had
six CTCs, resulting in the assignment of the patient into a different
risk group.45
For tdEVs, no manual scores can be obtained as the CellSearch
generated thumbnails do not include objects with only CK-PE.
Whether or not deep learning can be also used to improve
detection and classification of tdEVs remains, as of yet, unanswered.
Notably, ACCEPT tdEV counts are found in at least one order of
magnitude higher frequencies compared to CTCs in all different
cancer types, thereby confirming our previous findings in CRPC.14
The high degree of correlation between CTCs with tdEVs that we
found in CRPC, MBC and mCRC (Supplementary Fig. S1) can likely
be attributed to a similar shedding of tdEVs from the primary and
metastatic sites as with the CTCs. Origin of tdEVs by degradation of
CTCs after blood draw is unlikely, as the blood samples were
collected in CellSave tubes, which stabilises the cells in the blood,
preventing their degradation.46
One way for the clinicians to bring our findings into patient care
is by automatically extracting tdEV counts of the already
processed samples for CTCs; the tdEV count can serve as a
second biomarker to confirm the initial prognosis of the patient
based on their CTC counts. However, for the additional stratifica-
tion of patients with low (favourable) CTC counts reported here,
the tdEV cut-off values with the most significant correlation to OS
were chosen for each patient cohort. It is recommended that the
selected tdEV cut-off values be confirmed in additional studies to
derive more unequivocal conclusions.
In case of NSCLC patients, tdEVs are unable to further stratify
patients with favourable CTC counts. Moreover, both CTC and
tdEV counts, as defined by the CellSearch system, are very low
regardless the particular aggressiveness of the specific cancer
type. The question why remains open and has been discussed
elsewhere.47 Low expression of EpCAM and/or CK has been
suggested as possible explanations. The CellSearch yields a CTC
recovery of 87–91% when cells express 1.5–2.3 × 106 EpCAM
molecules.35 However, when EpCAM expression falls to 4.9–2.0 ×
103 EpCAM molecules, the respective CTC recovery drops to as low
as 2%.35 In case of the smaller tdEVs, lower magnetic forces and
subsequently EpCAM expression is required for their immuno-
magnetic isolation. Another critical point is the detection of
isolated EpCAM+ CTCs by the expression of CK8, 18 and 19.
Colleagues have previously demonstrated that androgen
receptor-positive (AR+) CTCs isolated by the CellSearch system
were not detectable by the CellTracks Analyzer II due to
insufficient CK expression.48 de Wit et al. also reported that, in
case of NSCLC patients, the inclusion of antibodies targeting more
CKs increased the detection of CTCs within the CellSearch
cartridges from 41% to 52%.35 Therefore, the use of additional
Tumour-derived extracellular vesicles in blood of metastatic cancer. . .
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Fig. 5 Overview plots of HRs (with 95% CIs) for all possible cut-off values for tdEV counts in CRPC (a), MBC (b) and mCRC (c) patients with
favourable CTC counts (<5 for CRPC and MBC and <3 for mCRC), as generated by the Cutoff Finder software. The optimal cut-offs, determined
as the point that resulted in the most significant split (log-rank test), are indicated by a vertical line in each plot. Kaplan–Meier plots for overall
survival in CRPC (d), MBC (e) and mCRC (f) patients with favourable CTC counts by favourable and unfavourable tdEV counts were generated
based on the optimal tdEV cut-off values. Favourable CTC patients with unfavourable (elevated) tdEV counts had significantly worse OS
compared to favourable CTC patients with favourable (below the selected cut-off values) tdEV counts.
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antibodies recognising membrane (EpCAM, VAR2CSA, HsP70,
PSMA, HER2, epidermal growth factor receptor 2 (EGFR2)) or
cytoplasmic (vimentin) markers could lead to increased detection
of CTCs and tdEVs that have been already positively selected
based on their EpCAM expression.
The inclusion of more specific antibodies in the staining mixture
could also aid in the discrimination of tdEVs from EVs secreted
from non-tumour epithelial cells in the bloodstream of healthy
individuals. The reason why only some of the healthy individuals
have detectable EVs defined as tdEVs (Fig. 2) could be explained
by a condition of liver inflammation/fibrosis that would result in
increased secretion of epithelial EVs. In alignment with that
hypothesis, Julich-Haertel et al. demonstrated that individuals with
cirrhosis have detectable EpCAM+ AnnexinV+ EVs in similar
frequencies to individuals with NSCLC and CRC.49
Genotypic characterisation of tdEVs in healthy individuals and
cancer patients would further confirm their origin. Molecular
profiling of the isolated tdEVs could provide us with a mutational
snapshot of the tumour during therapies and lead to a better
understanding of the underlying pathways and mechanisms that
promote progression. Jiang et al. identified AR mutations in
CellSearch-enriched blood samples of CRPC patients that did not
have any CellSearch-defined CTCs; some of the AR mutations that
were indicating resistance to AR-targeted therapies had been
found also in biopsies or autopsies of the respective patients.50
Furthermore, Marchetti et al. also reported EGFR mutations in
CellSearch-enriched blood samples of 84% NSCLC patients,
whereas only 41% of them were positive for CellSearch-defined
CTCs.51 These findings raise the question whether specific gene
mutations are present in EpCAM+ CTCs isolated by CellSearch but
missed by the system as CK− or whether these mutations are
encapsulated within the EpCAM+, CK+, CD45-, DNA- tdEVs that
we report here. Both hypotheses are likely to be true as supported
by the presence of CK− CTCs in the CellSearch cartridges48 and
the presence of most tumour DNA in large CK+ tdEVs found in the
plasma of cancer patients.10 In addition, it has been reported that
relevant gene mutation information is present in the plasma
fraction of blood samples, either encapsulated within EVs or as
cell-free tumour DNA.52,53
Our study has the limitation that all blood samples were
centrifuged at 800 × g for 10min and the plasma was aspirated
before being processed by the CellSearch system; hence, the
EpCAM+, CK+, DAPI−, CD45− fraction of tdEVs that we report
here was isolated from the blood cell pellet and it has a size range
between 1 and 14 μm. These large tdEVs constitute only a small
subset of probably <1% of the total tdEVs that are present in the
blood sample before centrifugation, based on the size estimations
of secreted EVs from model cancer cell lines.54–56
An approach to enrich and further investigate the smaller tdEVs
is to run plasma through the CellSearch system. A first attempt
indeed showed many CK+ tdEVs isolated from the plasma of a
CRPC patient by the CellSearch system, but improvements need to
be made for their detection and identification. Further character-
isation and downstream analysis of the EpCAM-enriched tdEVs
using gold standard techniques,57,58 also recommended by the
International Society of Extracellular Vesicles,59 can further elucidate
their biophysical properties. Towards that direction, the Cancer-ID
consortium was formed to identify and characterise tdEVs and
elucidate their differences from EVs of different origins. Electron
microscopy,60,61 nanoparticle tracking analysis, flow cytometry,62,63
Raman spectroscopy,64 surface plasmon resonance55 and atomic
force microscopy65 have been investigated for the characterisation
of tdEVs with or without EpCAM pre-enrichment. Principal
component analysis of Raman spectra shows clear discrimination
between EVs of cancerous cell and healthy blood cell origin.54
In conclusion, this study shows the simultaneous isolation and
detection of CTCs and large (1–14 μm) tdEVs in a single assay
(CellSearch) maximising the available data from individual
peripheral blood samples of metastatic cancer patients. Impor-
tantly, tdEVs have an equivalent prognostic power to CTCs in
CRPC, MBC, mCRC and NSCLC patients and can further stratify
patients with low/favourable CTC counts. Furthermore, the non-
stringent criteria used to classify an object as a tdEV allows for
their reliable and fast automated enumeration using the ACCEPT
software without the necessity of time-consuming training and
manual scoring by individual users. The presence of tdEVs in
higher frequencies, when compared to CTCs, may better reflect
the phenotypic heterogeneity of the tumour. That fact together
with the increased stability of EVs in circulation render tdEVs as a
promising biomarker for clinicians to evaluate the mutational
status, transcriptome and proteome of the tumour and the
presence of therapeutic targets that could predict treatment
responses of patient subsets with or without CTCs. Last but not
least, future research of EVs could contribute in the comprehen-
sion of the underlying mechanisms of the tumour to develop
resistance to treatments and open the path towards the
development of new therapies.
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